enzastaurin + carboplatin

Enzastaurin + carboplatin is an investigational combination therapy that comprises two drugs: enzastaurin, an oral small-molecule inhibitor of protein kinase C beta (PKCβ), and carboplatin, an intravenous platinum-based chemotherapeutic agent. Enzastaurin targets signaling pathways important in tumor angiogenesis and survival, while carboplatin induces DNA crosslinking, resulting in apoptosis in rapidly dividing cancer cells. This combination has been explored for the treatment of advanced solid tumors, particularly ovarian cancer, non-small cell lung cancer, and malignant gliomas. The therapeutic rationale involves synergistic cytotoxic and anti-angiogenic effects. Clinical studies have evaluated the combination mainly in the experimental setting, frequently as part of multidrug regimens that may include paclitaxel or pemetrexed[1][2][3][4][5].